Tibet Weixinkang Pharmaceutical announced that its wholly-owned subsidiary Baiyi Pharmaceutical's pediatric multi-vitamins injection will be renewed into the "National Medical Insurance Catalog" during the agreement period. This pharmaceutical is an exclusive variety, suitable for preventing vitamin deficiency in patients under 11 years old receiving parenteral nutrition. Sales revenue reached 45.507 million yuan in 2023, accounting for 3.44% of the company's current revenue; in the first three quarters of 2024, sales revenue reached 52.4323 million yuan, accounting for 5.27% of the company's current revenue. The inclusion in the medical insurance catalog this time will benefit the market promotion and sales of the product, further consolidating the company's market position in the field of intravenous vitamin supplements.